−0.3285EUR
−8.45 MEUR
102.00 KEUR
38.92 M
About CELYAD ONCOLOGY
Sector
Industry
CEO
Michel E. Lussier
Website
Headquarters
Mont-Saint-Guibert
Employees (FY)
17
Founded
2007
ISIN
BE0974260896
FIGI
BBG004NBYQW1
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of CYAD is 0.3260 EUR — it has decreased by 2.54% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange CELYAD ONCOLOGY stocks are traded under the ticker CYAD.
CELYAD ONCOLOGY is going to release the next earnings report on Sep 20, 2024. Keep track of upcoming events with our Earnings Calendar.
CYAD stock is 8.25% volatile and has beta coefficient of 1.32. Check out the list of the most volatile stocks — is CELYAD ONCOLOGY there?
CYAD earnings for the last quarter are −0.62 EUR whereas the estimation was −0.97 EUR which accounts for 36.37% surprise. Estimated earnings for the next quarter are −0.80 EUR. See more details about CELYAD ONCOLOGY earnings.
CELYAD ONCOLOGY revenue for the last quarter amounts to 0 EUR despite the estimated figure of 0 EUR. In the next quarter revenue is expected to reach 2.25 M EUR.
Yes, you can track CELYAD ONCOLOGY financials in yearly and quarterly reports right on TradingView.
CYAD stock has fallen by 2.10% compared to the previous week, the month change is a 6.86% fall, over the last year CELYAD ONCOLOGY has showed a 50.00% decrease.
CYAD net income for the last quarter is −4.71 M EUR, while the quarter before that showed −3.74 M EUR of net income which accounts for −25.88% change. Track more CELYAD ONCOLOGY financial stats to get the full picture.
Today CELYAD ONCOLOGY has the market capitalization of 13.86 M, it has increased by 4.32% over the last week.
No, CYAD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, CYAD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CELYAD ONCOLOGY stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 17.00 employees. See our rating of the largest employees — is CELYAD ONCOLOGY on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CELYAD ONCOLOGY technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CELYAD ONCOLOGY stock shows the sell signal. See more of CELYAD ONCOLOGY technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CELYAD ONCOLOGY EBITDA is −9.82 M EUR, and current EBITDA margin is −9.61 K%. See more stats in CELYAD ONCOLOGY financial statements.